argenx SE (ARGX) Earnings Date & Reports

Key Takeaways

• argenx reported third quarter 2026 total revenue of $1.75 billion, up from $1.15 billion in the prior-year period.
• Product net sales of Vyvgart reached $1.72 billion, rising 54% year over year and 13% quarter over quarter.
• Net income climbed to $506 million, with diluted earnings per share (EPS) of $7.80 versus $5.18 a year earlier.
• Vyvgart sales beat consensus, but operating profit of $486 million came in below analyst expectations.
• The company now expects combined research and development (R&D) and selling, general and administrative (SG&A) expenses of roughly $4 billion for full-year 2026.

Earnings Context and Why It Matters

argenx SE, a Belgium-based immunology company, has built its growth story around Vyvgart (efgartigimod), a treatment for autoimmune conditions including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). This quarterly report carries added weight because it reflects the company's first results since closing its acquisition of Forte Biosciences, a move that expanded its pipeline and reshaped its near-term expense profile. For investors, the print offers a key read on whether Vyvgart's commercial momentum can keep funding a growing research pipeline while the company absorbs acquisition-related costs. The results also test management's guidance on operating leverage heading into 2027.

Reported Results

Total revenue for the three months ended September 30, 2026 was $1.751 billion, up from $1.151 billion in the same period of 2025. Product net sales of Vyvgart reached $1.72 billion, a 54% year-over-year increase, driven by continued patient growth across gMG and CIDP. Net income rose to $506 million from $344 million a year earlier, with basic EPS of $8.07 compared to $5.61 and diluted EPS of $7.80 compared to $5.18.

On a nine-month basis, revenue reached $4.605 billion versus $2.926 billion in the prior year, while net income climbed to $1.344 billion from $759 million. The company reported operating profit of $486 million, reflecting a 28% operating margin, or 37% when adjusted for one-time Forte transaction costs. Combined R&D and SG&A expenses totaled $1.1 billion for the quarter, up 22% sequentially, including about $150 million of acquisition-related costs. The company ended the quarter with $3.7 billion in cash, cash equivalents, and current financial assets after paying roughly $2.1 billion, net of acquired cash, for Forte Biosciences.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, giving investors a faster way to surface names that match their specific criteria. Explore the AI Screener to build a focused watchlist aligned with your own research process.

Market Reaction and Investor Sentiment

Investor response to the print was mixed. Vyvgart sales of $1.72 billion came in about 6% above consensus estimates, and total revenue of $1.75 billion also exceeded expectations, underscoring the strength of the franchise. However, operating profit of $486 million landed roughly 11% below the Visible Alpha consensus, reflecting higher-than-anticipated spending tied to the Forte acquisition and broader pipeline investments. Shares showed choppy trading around the release, initially easing as the operating profit miss offset the revenue beat. Management's commentary on continued margin expansion in 2027 and its confidence in underappreciated top-line growth helped frame the results for analysts, though the near-term expense guidance remained a key focus of the reaction.

Forward Outlook and Key Factors to Monitor

argenx has raised its full-year 2026 expense outlook, now expecting combined R&D and SG&A spending of approximately $4 billion, including Forte transaction costs and investment into FB-102, the celiac disease candidate acquired through the Forte deal. Management has signaled that it expects to keep expanding operating margin into 2027, with more detailed guidance anticipated early next year.

Investors should watch several catalysts closely. The company is advancing supplemental regulatory filings for Vyvgart in ocular and pediatric myasthenia gravis, with a pediatric review decision date set for February 2027. It is also preparing to move FB-102 into a Phase 3 trial in celiac disease and is pursuing immune-mediated necrotizing myopathy (IMNM) as a potential next indication for the Vyvgart franchise.

At the same time, argenx recently discontinued a trial in Sjögren's disease, with full data analysis still pending. The balance between rising investment and the pace of revenue growth will remain central to the story, as will the company's ability to sustain patient growth in gMG and CIDP while expanding into new markets. The next full update is scheduled for February 25, 2027, when the company reports full-year 2026 results.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations